| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Camzyos (mavacamten) Obstructive hypertrophic cardiomyopathy (oHCM) in adolescents (ages 12 to <18 years) | Phase 3 | — | Small Molecules | Cardiovascular System | ||
Phase 3 data readout example | Camzyos (mavacamten) Obstructive hypertrophic cardiomyopathy (oHCM) in adolescents (ages 12 to <18 years) | Phase 3 | — | Small Molecules | Cardiovascular System | ||
Phase 3 data readout example | Camzyos (mavacamten) Obstructive hypertrophic cardiomyopathy (oHCM) in adolescents (ages 12 to <18 years) | Phase 3 | — | Small Molecules | Cardiovascular System |
Recent Updates
Recently added Catalysts
Bristol-Myers Squibb Company$56.44
-1.05 (-1.82%)
A 94Pipeline Score Undervalued Pharma · Commercial
Market Cap
121.42 B
EPS
3.57
P/E Ratio
16.69 $
Value Trade
631.78 M
SEC Financials
Q1 2026Dilution Risk
Revenue
11.49 B
R&D Expenses
2.65 B
Operating CF
1.10 B
Total Assets
86.48 B
Total Liabilities
66.37 B
Equity
20.07 B
D/E Ratio
12,345
4.98 %
Week
0.1 %
1 Month
-1.91 %
3 Month
28.78 %
6 Month
-11.57 %
5 Year
2,822.58 %
All Time
Cash Data
Cash Position
10.49 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 30, 2026
Overview
Volume
10.96 M
52 Week Range
42.52 - 62.89
% held by Insiders
0.32 %
% held by Institutions
83.63 %
Enterprise Value
157.40 B
Total Shares
2.04 B
Short %
1.95 %
Float Shares
2.04 B
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
A94
Pipeline Score $120.3B
Pipeline ValueUndervalued
Valuation Signal414
Drugs Scored3.3x
rNPV / MCap Top 100%
Large Pharma (rank 1 of 905)
Percentile RankBristol-Myers Squibb Company earns an A-grade pipeline score (94/100), with $120.3B risk-adjusted pipeline value, led by muraglitazar in Diabetes Mellitus, Type 2 (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| muraglitazar Small molecule | Diabetes Mellitus, Type 2 | Phase 3 | NCT00095030 | 53% | $13.6B | COMPLETED | 1,794 | - | - | Mar 1, 2006 | - | Sep 14, 2010 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
luspatercept | anemia in adults with Alpha (α)-Thalassemia | Phase 2 | 2026-02-23 | |||
luspatercept | anemia in adults with Alpha (α)-Thalassemia | Phase 2 | 2026-02-23 | |||
luspatercept | anemia in adults with Alpha (α)-Thalassemia | Phase 2 | 2026-02-23 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BMY
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Bristol-Myers Squibb Company (BMY) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
BMY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BMY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BMY
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BMY Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
BMY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-10 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-10 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-10 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BMYBristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026
Bristol Myers Squibb is scheduled to report its financial results for the second quarter of 2026 on July 30, 2026. This announcement is part of the company's regular financial reporting cycle. Investors and analysts will be looking for insights into the company's performance during this period.
Read more →BMYBristol Myers Squibb Announces Dividend
Bristol Myers Squibb has announced a dividend, indicating a commitment to returning value to shareholders. However, the article lacks specific details about the dividend amount or the context surrounding this decision. The announcement reflects the company's ongoing financial strategy.
Read more →BMYBristol Myers Squibb Appoints Mayada Al-Ahmad as General Manager for Saudi Arabia & Gulf Countries
Bristol Myers Squibb has appointed Mayada Al-Ahmad as General Manager for Saudi Arabia and Gulf Countries, effective June 1, 2026. With over 24 years of experience in the pharmaceutical sector, she will lead efforts to deliver transformative medicines across the region. Her appointment aligns with BMS's mission and regional health priorities.
Read more →BMYMariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease
Mariska Hargitay has partnered with Bristol Myers Squibb to launch the 'Investigating Myeloma' awareness campaign. This initiative aims to honor her father, who passed away from the disease 20 years ago. The campaign seeks to raise awareness about myeloma and its impact on patients and families.
Read more →BMYBristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb announced positive results from the Phase 3 SUCCESSOR-2 trial, showing that mezigdomide combined with carfilzomib and dexamethasone significantly reduces the risk of disease progression or death in patients with relapsed or refractory multiple myeloma. The trial demonstrated a median progression-free survival of 18 months, highlighting mezigdomide's potential as a new standard of care. The results were presented at the 2026 ASCO Annual Meeting.
Read more →BMYBristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Bristol Myers Squibb has announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference scheduled for June 9, 2026. The company will engage in a fireside chat at 2:00 p.m. ET, which will be accessible to investors and the public. An archived version of the session will be available post-event.
Read more →BMYBristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
Bristol Myers Squibb will present new data at the 2026 ASCO Annual Meeting, showcasing the potential of mezigdomide and other innovative therapies in their oncology portfolio. The company will highlight over 60 disclosures, including advancements in solid tumors and hematologic malignancies. Key presentations will focus on targeted protein degradation and novel treatment combinations.
Read more →BMYBristol Myers Squibb Reports First Quarter Financial Results for 2026 Financial Results Reflect Strong Execution and a Strengthened Foundation with Significant Pipeline Milestones Ahead First quarter revenues increased 3
Bristol Myers Squibb (BMY) has reported its first quarter financial results for 2026, indicating a 3% increase in total revenues to $11.5 billion. While the growth portfolio experienced notable gains, the legacy portfolio faced a decline due to ongoing generic competition. Adjusted EPS figures showed some decreases compared to 2025, although the company reaffirmed its 2026 financial projections. Additionally, several significant pipeline milestones are on the horizon, showcasing the company's ongoing commitment to advancement in therapeutics.
Read more →BMYFoundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion
Foundation Medicine has expanded its collaboration with Bristol Myers Squibb to develop a next-generation sequencing companion diagnostic, FoundationOne CDx, aimed at identifying patients with homozygous MTAP deletion. This advancement is crucial for targeted therapies in multiple indications. The partnership emphasizes the importance of accurate biomarker detection in precision oncology.
Read more →BMYOxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours
Oxford BioTherapeutics has entered a strategic collaboration with Bristol Myers Squibb to develop next-generation T-cell engagers for solid tumors. This partnership, leveraging OBT's OGAP®-Verify platform, marks OBT's third major collaboration in a year, reflecting confidence in its drug development capabilities. Financial terms remain undisclosed, but OBT will receive upfront payments and potential royalties.
Read more →BMYOpen Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
Bristol Myers Squibb announced positive results from a Phase 4 trial of Cobenfy, demonstrating stability in patients transitioning from oral atypical antipsychotics to Cobenfy monotherapy. The trial showed high treatment completion rates and no new safety signals. The findings will aid clinicians in making informed treatment decisions for schizophrenia.
Read more →BMYBristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
Bristol Myers Squibb announced positive results from the Phase 3 SCOUT-HCM trial of Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The trial met its primary endpoint, showing a significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28. Additionally, the safety profile was consistent with that seen in adults, with no new safety concerns. These findings may lead to a new treatment option for this patient population.
Read more →BMYBristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
Bristol Myers Squibb announced that Opdivo (nivolumab) has received FDA approval for use in combination with AVD for treating previously untreated Stage III or IV classical Hodgkin Lymphoma (cHL) in patients aged 12 and older. Additionally, the European Commission approved Opdivo in combination with brentuximab vedotin for certain relapsed or refractory cHL patients. These approvals signify a major breakthrough in treatment options for cHL, supported by clinical studies demonstrating improved patient outcomes.
Read more →BMYinsitro and Bristol Myers Squibb Collaboration Expanded with Nomination of New Targets
Insitro has expanded its collaboration with Bristol Myers Squibb to enhance its portfolio of therapeutic programs targeting amyotrophic lateral sclerosis (ALS). The partnership aims to accelerate the development of disease-modifying interventions that address the biological drivers of ALS. Bristol Myers Squibb has nominated two additional targets as part of this initiative.
Read more →BMYU.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
The U.S. FDA has approved Bristol Myers Squibb's Sotyktu (deucravacitinib) for treating adults with active psoriatic arthritis. This approval is based on positive results from the Phase 3 POETYK PsA-1 and POETYK PsA-2 trials, which demonstrated significant efficacy. Sotyktu is the first TYK2 inhibitor approved for this condition, addressing a critical need in treatment options.
Read more →BMYBristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb announced positive interim results from the SUCCESSOR-2 Phase 3 study, showing that oral mezigdomide combined with carfilzomib and dexamethasone significantly improves progression-free survival in patients with relapsed or refractory multiple myeloma. The findings highlight the potential of mezigdomide as a new treatment option. Safety results were consistent with known profiles.
Read more →BMYBristol Myers Squibb Announces Dividend - March 2, 2026
Bristol Myers Squibb has declared a quarterly dividend of $0.63 per share, payable on May 1, 2026. This dividend is for stockholders of record as of April 2, 2026. The announcement highlights the company's commitment to returning value to its shareholders while continuing its mission to develop innovative medicines.
Read more →BMYSystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
SystImmune and Bristol Myers Squibb announced positive interim results from a Phase III study of izalontamab brengitecan (iza-bren) in patients with unresectable locally advanced or metastatic triple-negative breast cancer. The study met its dual primary endpoints of progression-free survival and overall survival, marking a significant advancement in treatment options for this patient population. The results highlight the potential of bispecific antibody-drug conjugates in oncology.
Read more →BMYBristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
Bristol Myers Squibb announced its participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 2, 2026. The company will engage in a fireside chat at 9:50 a.m. ET, which will be accessible to investors and the public via their investor website. An archived version of the session will be available afterward.
Read more →BMYBristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
Bristol Myers Squibb announced positive top-line results from a Phase 2 study of luspatercept for anemia in adults with alpha-thalassemia. The study demonstrated significant improvements in hemoglobin levels for non-transfusion-dependent patients and reduced transfusion needs for transfusion-dependent patients. All primary and secondary endpoints were met, supporting the drug's potential in treating this condition.
Read more →BMYU.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
Bristol Myers Squibb announced that the FDA has accepted its New Drug Application for iberdomide, a treatment for relapsed or refractory multiple myeloma. The application is based on data from the ongoing Phase 3 EXCALIBER-RRMM study, which evaluates iberdomide in combination with standard therapies. The FDA has set a PDUFA date of August 17, 2026, and granted Breakthrough Therapy designation for iberdomide.
Read more →BMYBristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
Bristol Myers Squibb has announced its financial results for the fourth quarter and full year of 2025. The company will host a conference call for analysts and investors to discuss these results in detail. The call is scheduled for February 5, 2026, and will be accessible via a live audio webcast.
Read more →BMYBristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi
Bristol Myers Squibb has partnered with Kasey Keller to share his personal experience with non-Hodgkin lymphoma and his successful treatment with Breyanzi, a CAR T cell therapy. Keller aims to empower others facing similar challenges by discussing his journey and the importance of understanding treatment options. This initiative coincides with World Cancer Day, emphasizing the need for greater awareness in blood cancer treatment.
Read more →BMYBristol Myers Squibb Introduces “Change the Target. Change What’s Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care
Bristol Myers Squibb has launched an educational campaign titled 'Change the Target. Change What’s Possible.' in collaboration with Johnson & Johnson. This initiative aims to address the unmet needs in cardiovascular and thromboembolic care, particularly for patients at high risk of thromboembolic events. The campaign emphasizes the potential of targeting factor XIa to improve treatment outcomes and reduce the risk of dangerous clots without increasing bleeding risk.
Read more →BMYBristol Myers Squibb Introduces "Change the Target. Change What’s Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care
Bristol Myers Squibb has launched the "Change the Target. Change What’s Possible." campaign to address unmet needs in cardiovascular and thromboembolic care. The initiative highlights the significant risks faced by patients, particularly those with atrial fibrillation, and emphasizes the potential of targeting factor XIa to improve treatment outcomes. The collaboration with Johnson & Johnson aims to leverage expertise in addressing these challenges.
Read more →BMYBristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
Bristol Myers Squibb has partnered with Microsoft to enhance early detection of lung cancer using AI-driven radiology solutions. The collaboration will deploy FDA-cleared algorithms through Microsoft's Precision Imaging Network, aiming to improve patient outcomes and streamline workflows. A key focus is on expanding access to early detection in medically underserved areas, addressing health disparities in lung cancer care.
Read more →BMYBristol Myers Squibb: Built for Growth 44th Annual J.P. Morgan Healthcare Conference Christopher Boerner, Ph.D., Board Chair & CEO January 12th, 2026 Forward Looking Statements 2 This presentation (as well as the oral st
Bristol Myers Squibb showcased its growth strategy during the 44th Annual J.P. Morgan Healthcare Conference, led by CEO Christopher Boerner, Ph.D. The company aims to deliver sustainable growth into the 2030s through strong execution and a focus on its growth portfolio. Key highlights include a 17% increase in portfolio sales, advancements in crucial pipeline programs, and a commitment to addressing significant healthcare needs. However, potential regulatory changes and challenges in securing milestones pose risks to these objectives.
Read more →BMYBristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference
Bristol Myers Squibb has announced its participation in the J.P. Morgan 44th Annual Healthcare Conference on January 12, 2026. The presentation will include a fireside chat and will be available via webcast. This event highlights the company's commitment to innovation in medicine.
Read more →BMYBristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
Bristol Myers Squibb (BMS) has announced a significant agreement with the U.S. government to provide Eliquis, an oral anticoagulant, for free to the Medicaid program. This initiative aims to enhance access to critical medicines for vulnerable populations while also donating over seven tons of Eliquis active pharmaceutical ingredient to bolster supply chain resilience. The agreement aligns with BMS's commitment to improving cardiovascular health and reducing healthcare costs.
Read more →BMYU.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
Bristol Myers Squibb announced that the FDA has accepted its supplemental Biologics License Application for Opdivo (nivolumab) in combination with chemotherapy for treating previously untreated Stage III or IV classical Hodgkin lymphoma. The FDA has granted priority review, with a PDUFA goal date of April 8, 2026. This combination therapy is anticipated to become a new standard of care for patients, addressing a significant need for effective treatment options.
Read more →BMYBristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
Bristol Myers Squibb presented over 95 data disclosures at the 67th ASH Annual Meeting, emphasizing advancements in their hematology portfolio. Key highlights include promising data from targeted protein degradation and cell therapy research platforms, particularly for multiple myeloma and lymphomas. The company aims to redefine treatment paradigms with innovative therapies while acknowledging the risks associated with their use.
Read more →BMYBristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference
Bristol Myers Squibb (BMY) will participate in Citi's 2025 Global Healthcare Conference on December 4, 2025. The company is set to engage in a fireside chat at 9:00 a.m. ET, which will be accessible to investors and the public online. An archived version of the session will be available post-event.
Read more →BMYBristol Myers Squibb to Host Hematology-Focused Investor Event
Bristol Myers Squibb has announced a virtual investor event scheduled for December 11, 2025, following the American Society of Hematology Annual Meeting. The event will focus on the company's Hematology programs, providing an overview of their development strategy and recent data. A replay of the webcast will be available shortly after the event concludes.
Read more →BMYAbout Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We
Bristol Myers Squibb has announced the early participation results of its tender offers for outstanding notes. The company is adjusting the maximum purchase prices for both Pool 1 and Pool 2 Notes, aiming to accept all validly tendered notes before the Early Tender Deadline. Notably, all Pool 1 Notes and certain Pool 2 Notes tendered will be accepted, without proration. The withdrawal rights for these offers have expired, and the company plans to execute early settlement on November 20, 2025.
Read more →BMYBristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes (Princeton, N.J.
Bristol Myers Squibb has launched cash tender offers valued at up to $4 billion to purchase certain outstanding notes, which include various securities due in the coming years. The offers are structured in two priority pools, allowing for specific acquisitions based on acceptance criteria. Noteholders are provided a deadline for an early tender premium, with expected funding sourced from new debt issuance and existing cash reserves. This initiative aims to manage outstanding debts effectively while providing cash liquidity to noteholders.
Read more →BMYBristol Myers Squibb Reports Third Quarter Financial Results for 2025 Performance Marked by Continued Growth Portfolio Momentum, Pipeline Advancements and Strategic Business Development Third quarter revenues increased 3
Bristol Myers Squibb reported a 3% revenue increase for Q3 2025, reaching $12.2 billion, driven by an 18% rise in Growth Portfolio revenues. The company raised its 2025 revenue guidance to between $47.5 billion and $48.0 billion amid ongoing pipeline advancements. However, the Legacy Portfolio faced challenges, with a 12% revenue decline impacted by generic competition. Non-GAAP EPS also saw a 9% decrease compared to the previous year.
Read more →BMYYears of Global Patient Week: Bristol Myers Squibb Brings Joy to Patients with Toy-Making Workshops Across the Region Underscoring its unwavering commitment to patient-centricity, Bristol Myers Squibb, a leading global biopharmaceutical company, marked the 11th...
Bristol Myers Squibb celebrated the 11th anniversary of Global Patient Week through toy-making workshops in Saudi Arabia and the UAE. These initiatives involved employees collaborating with local advocacy groups to create handmade toys for children battling thalassemia and cancer. The workshops not only provided joy to the young patients but also emphasized the company's dedication to patient support beyond medication. Additionally, the event included a blood donation drive to further reinforce community health and awareness.
Read more →BMYBristol Myers Squibb Reports Second Quarter Financial Results for 2025 Performance Underscores Continued Execution Against Long-Term Growth Strategy Second quarter revenues were $12.3 billion Growth Portfolio revenues we
Bristol Myers Squibb announced their second quarter financial results for 2025, reporting revenues of $12.3 billion, a slight increase from the previous year. The Growth Portfolio, primarily driven by immuno-oncology products, saw an 18% revenue increase, while the Legacy Portfolio experienced a 14% decline. The company has raised its revenue guidance for 2025, reflecting ongoing progress in its long-term growth strategy. Despite revenue growth, there were declines in GAAP EPS, highlighting some challenges in their overall financial performance.
Read more →BMYCristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development Dr. Massacesi will join BMS August 1 and serve on the Executive Leadership Team Samit Hirawa
Bristol Myers Squibb (BMY) has appointed Cristian Massacesi, M.D., as the new Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. Massacesi, who previously served as Chief Medical Officer at AstraZeneca, will oversee the company's product development across various therapeutic areas. He replaces Samit Hirawat, M.D., who is departing BMS to pursue other opportunities. The transition has been planned to ensure continued progress in innovative drug development.
Read more →BMYBristol Myers Squibb Reports First Quarter Financial Results for 2025 Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution First quarter revenues were $11.2 billion , -6% (-4% Ex-FX) Growth Portf
Bristol Myers Squibb reported its financial results for the first quarter of 2025, revealing total revenues of $11.2 billion, a 6% decrease compared to the previous year. Despite this decline, the company's Growth Portfolio, which includes products such as Opdivo and Breyanzi, saw revenues rise by 16%. The firm has raised its revenue guidance for 2025 and reported a significant improvement in non-GAAP earnings per share. However, the overall drop in U.S. revenues emphasizes challenges the company faces in maintaining market dominance.
Read more →BMYBristol Myers Squibb Appoints Osama Braiwish as General Manager for Saudi Arabia & Gulf Countries Bristol Myers Squibb, a leading global biopharmaceutical company, has recently appointed Osama Braiwish as its General Manager for Saudi Arabia and...
Bristol Myers Squibb has appointed Osama Braiwish as the General Manager for Saudi Arabia and Gulf Countries. Braiwish brings over 25 years of experience in the pharmaceutical industry and is expected to drive growth and innovation in the region. The appointment aligns with BMS's strategy to enhance access to therapies, particularly in areas with significant healthcare needs. Senior executives expressed confidence in Braiwish's leadership to foster collaborations and improve healthcare outcomes.
Read more →BMYBristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024 Performance Reflects Progress Toward Delivering Sustained, Top-Tier Growth Fourth Quarter Revenues were $12.3 Billion, Increasing 8% (+
Bristol Myers Squibb reported its fourth quarter and full-year financial results for 2024, indicating an overall revenue increase driven by a strong growth portfolio. The total fourth quarter revenues rose to $12.3 billion, reflecting an 8% year-over-year growth. However, the company also reported a substantial loss in GAAP earnings per share, driven by impairment charges and pressures on its Legacy Portfolio due to generics. Noteworthy achievements included the U.S. approval of Cobenfy and a strategic plan to save $2 billion by 2027.
Read more →BMYrd Annual J.P. Morgan Healthcare Conference January 13th, 2025 Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer Forward Looking Statements and Non-GAAP Financial Information 2 This presentation (as wel
Bristol-Myers Squibb (BMY) outlines its forward-looking strategy at the 43rd Annual J.P. Morgan Healthcare Conference, highlighting its ambition for sustained top-tier growth by 2025. The company is focused on its advanced growth portfolio, aiming to exceed 50% of overall revenues by that year, supported by key marketed products and new clinical data. Cobenfy, its new treatment for schizophrenia, demonstrates strong early performance, while the company pursues strategic acquisitions to enhance financial stability. Despite the optimistic outlook, the company acknowledges potential risks related to regulatory processes and market conditions.
Read more →BMYBristol Myers Squibb Reports Third Quarter Financial Results for 2024 Performance Reflects Continued Focus on Near-Term Execution and Building a Foundation for Long-Term Sustainable Growth Third Quarter Revenues were $11
Bristol Myers Squibb reported third quarter 2024 financial results, showing a revenue increase of 8% year-over-year, reaching $11.9 billion. The company achieved U.S. approval for Cobenfy, the first new pharmacological approach to treat schizophrenia in decades. However, GAAP earnings per share saw a significant drop of 35%, influenced by generic erosion of Sprycel and increasing acquisition costs. Despite these challenges, the company raised its 2024 revenue guidance, reflecting confidence in future growth.
Read more →BMYBristol Myers Squibb Marks 10 Years of Global Patient Week with Community Initiatives in the Region To mark the 10th anniversary of its Global Patient Week, Bristol Myers Squibb, a leading global biopharmaceutical company, organized patient-focused...
Bristol Myers Squibb celebrated the 10th anniversary of its Global Patient Week with community initiatives in the UAE and Saudi Arabia. The company hosted a blood donation drive in Dubai, aimed at raising awareness about blood donation's importance for patients with blood disorders. In Saudi Arabia, they partnered with Sheryan Society to organize a puppet show for children battling Thalassemia, fostering joy and hope. These events emphasize the company's commitment to patient-centered care and community support.
Read more →BMYBristol Myers Squibb Reports Second Quarter Financial Results for 2024 Results Underscore Continued Progress on Commercial Execution, Driving the Growth Portfolio and Pipeline Advancement Second Quarter Revenues were $12
Bristol Myers Squibb reported strong second quarter financial results for 2024, with total revenues of $12.2 billion, marking a 9% year-on-year increase. The company's Growth Portfolio saw a remarkable 18% revenue increase, mainly attributed to successful products like Opdivo and Reblozyl. Despite a decrease in GAAP earnings per share due to higher expenses, the company raised its non-GAAP guidance, suggesting confidence in future growth prospects. Additionally, the U.S. approval for Breyanzi enhances the company's oncology offerings, and ongoing regulatory submissions for their pipeline drugs indicate continued momentum in research and development.
Read more →BMYBristol Myers Squibb Elects Michael R. McMullen to Board of Directors (Princeton, N.J.
Bristol Myers Squibb has elected Michael R. McMullen to its Board of Directors, effective July 1, 2024. McMullen, who previously served as CEO of Agilent Technologies, is expected to contribute valuable experience in managing large businesses and global operations. The board's chair expressed confidence that McMullen's expertise will support the company in strengthening its growth profile and maximizing opportunities. This appointment increases the Board's size to 11 members.
Read more →BMYBristol Myers Squibb Reports First Quarter Financial Results for 2024 Performance Reflects Execution and Actions to Strengthen the Company's Long-Term Growth Profile First Quarter Revenues were $11.9 Billion, increasing
Bristol Myers Squibb reported its first quarter financial results for 2024, showing revenues of $11.9 billion, a 5% increase from the previous year. The company's growth portfolio saw significant contributions, especially from products like Eliquis and Reblozyl, despite some challenges in legacy product sales. The completion of several strategic acquisitions positions the company for enhanced growth, although it reported a substantial GAAP loss per share due to recent IPRD charges. Overall, BMY is focusing on efficiency and innovation to drive future growth.
Read more →BMYBristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio KarXT, Karuna's Lead Asset, Is a Potential First-in-Class Treatment for Schizophrenia with Multi-Billion Dollar Sale
Bristol Myers Squibb has acquired Karuna Therapeutics, integrating it as a wholly owned subsidiary to enhance its neuroscience portfolio. This acquisition focuses on KarXT, a potential first-in-class treatment for schizophrenia, which has a PDUFA date set for September 26, 2024. Despite the anticipated financial impacts of the acquisition, which include a dilutive effect on earnings, BMS aims to leverage Karuna's innovative assets for future growth and secure its position in the biopharmaceutical market.
Read more →BMYBristol Myers Squibb Recommends Stockholders Reject "Mini-Tender" Offer by Tutanota LLC (Princeton, N.J.
Bristol Myers Squibb (BMY) has advised its stockholders to reject a mini-tender offer from Tutanota LLC to purchase shares at $55 each. The company warns that this offer is contingent on various conditions, including the market price exceeding the offer price, which currently it does not. Bristol Myers Squibb highlights the risk of stockholders receiving below-market prices and expresses concern about the potential delays in payment if the offer is extended. Stockholders who have already tendered their shares can withdraw them before the specified deadline.
Read more →BMYBristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023 Results Reflect Continued Strength of In-Line and New Products, Pipeline Execution and Business Development Activity, Supporting Growth
Bristol Myers Squibb reported its financial results for the fourth quarter and full year of 2023, showcasing a 1% year-over-year increase in quarterly revenues to $11.5 billion. The company noted strong performance in its new product portfolio, which saw a significant 71% growth. However, total revenues for the year showed a decline of 2% compared to the previous year, and performance in legacy products, particularly Revlimid, lagged. Moving forward, the company projects low single-digit revenue growth for 2024 backed by ongoing strategic collaborations and pipeline advancements.
Read more →BMYBristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety Ka
Bristol Myers Squibb (BMY) announced its acquisition of Karuna Therapeutics for $330 per share, totaling about $14 billion. This strategic move aims to enhance BMY's neuroscience portfolio, particularly with KarXT, a novel treatment showing promise for schizophrenia and potentially Alzheimer's. The transaction is anticipated to close in early 2024, pending regulatory approvals. While the acquisition is expected to boost growth, it may also impact BMY's earnings per share in the short term due to the financing strategy involved.
Read more →BMYBristol Myers Squibb amplia seu compromisso de longa data com a pesquisa do câncer por meio de seu passeio ciclístico Continent 2 Continent 4 Cancer Hoje, a Bristol Myers Squibb inicia o Continent 2 Continent 4 Cancer (C2C4C), um evento de ciclismo de 12 dias na América Latina para pesquisas sobre ...
Bristol Myers Squibb has launched the 'Continent 2 Continent 4 Cancer' cycling event, a 12-day initiative in Latin America aimed at raising funds for cancer research. Marking a decade of commitment to cancer fundraising, the event will support organizations like the A.C.Camargo Cancer Center in Brazil. Over 55 employees will cycle nearly 1,500 kilometers between Chile's Pucón and Puerto Varas, representing a deeply personal pursuit for many involved. The initiative has raised over $14 million globally, showcasing the dedication of Bristol Myers Squibb to improving cancer treatment and patient experiences.
Read more →BMYDia Nacional de Combate ao Câncer: primeiro bloqueador de checagem imunológica completa 10 anos de lançamento no Brasil, trazido pela Bristol Myers Squibb(1) O dia 27 de novembro marca o Dia Nacional de Combate ao Câncer, doença caracterizada pelo crescimento desordenado de células, que podem invadir...
On November 27, Brazil marks the National Cancer Combat Day, highlighting the rise in cancer cases and treatment development. Bristol Myers Squibb celebrates 10 years since the approval of the first immune checkpoint inhibitor, which has transformed cancer therapy since its introduction in 2013. This milestone underscores the importance of immunotherapy in enhancing the body's natural defenses against cancerous cells. The increased focus on cancer research continues to bring positive prospects for patients. The company reaffirms its mission to provide innovative treatments for serious diseases.
Read more →BMYBristol Myers Squibb Reports Third Quarter Financial Results for 2023 Reports Third Quarter Revenues of $11.0 Billion Posts Third Quarter GAAP Earnings Per Share of $0.93 and Non-GAAP EPS of $2.00 Includes Net Impact of
Bristol Myers Squibb reported its third quarter financial results for 2023, showing revenues of $11.0 billion, a slight decrease from the previous year. Despite the drop, the company reported a 24% increase in GAAP earnings per share and raised its Non-GAAP EPS guidance midpoint. Strategic moves included the planned acquisition of Mirati Therapeutics to strengthen its oncology portfolio and revenue growth from in-line and new products. However, the company's gross margin showed a decline, primarily due to changes in product mix and lower sales from Revlimid.
Read more →BMYANS abre consulta pública para incorporação de tratamentos do mieloma múltiplo recidivado refratário A Bristol Myers Squibb trabalha todos os dias para descobrir, desenvolver e disponibilizar medicamentos inovadores que ajudam os pacientes a superar...
Bristol Myers Squibb is actively engaged in innovative drug development for patients with multiple myeloma. Recently, the National Agency for Supplementary Health (ANS) announced public consultations to consider the incorporation of new therapies for relapsed and refractory multiple myeloma. If approved, these treatments could enter the mandatory healthcare coverage list in Brazil, providing new options for patients. Community feedback is being sought through public participation, highlighting the importance of collective input in healthcare advancements.
Read more →BMYImunoterapia aumenta a sobrevida de pacientes com câncer de pulmão em estágio avançado[i] O câncer de pulmão é o segundo mais comum no mundo, ficando atrás apenas do câncer de próstata nos homens e do de mama em mulheres[ii]. Entre as...
A imunoterapia tem mostrado resultados promissores no tratamento do câncer de pulmão em estágio avançado, permitindo que o sistema imunológico dos pacientes combata as células cancerígenas de forma mais eficaz. Esta abordagem terapêutica, que restaura a capacidade do sistema imunológico de identificar e atacar tumores, apresenta menos toxicidade em comparação com tratamentos tradicionais como a quimioterapia. Com a capacidade de prolongar a vida dos pacientes e melhorar sua qualidade de vida, esta terapia é considerada um marco na oncologia moderna.
Read more →BMYBristol Myers Squibb Reports Second Quarter Financial Results for 2023 Reports Second Quarter Revenues of $11.2 Billion Posts Second Quarter GAAP Earnings Per Share of $0.99 and Non-GAAP EPS of $1.75 Includes Net Impact
Bristol Myers Squibb announced its second-quarter financial results for 2023, reporting revenues of $11.2 billion, a 6% decline from the previous year. The company saw a significant increase in GAAP earnings per share, reaching $0.99. Notably, revenue growth was observed in in-line and new product portfolios, particularly with a 79% increase in new products. However, the ongoing decline in Revlimid sales has led to a revised outlook, reducing expectations for overall revenues in the year.
Read more →BMYAnvisa aprova CAMZYOS® (Mavacanteno) para o tratamento da cardiomiopatia hipertrófica obstrutiva sintomática(11) A ANVISA (Agência Nacional de Vigilância Sanitária) aprovou CAMZYOS® (mavacanteno) para o tratamento de adultos com cardiomiopatia hipertrófica (CMH) ...
Bristol Myers Squibb's CAMZYOS® (mavacanteno) has received approval from ANVISA for treating adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) of NYHA classification II and III. This medication is the first and only cardiac myosin inhibitor approved in Brazil, aiming to address the underlying pathophysiology of the condition. HCM affects approximately 500,000 adults in Brazil, but is frequently underdiagnosed, with around 85% of cases remaining unidentified. The approval is expected to enhance the management and treatment of this serious heart condition.
Read more →BMYBristol Myers Squibb Reports First Quarter Financial Results for 2023 Reports First Quarter Revenues of $11.3 Billion Posts First Quarter GAAP Earnings Per Share of $1.07 and Non-GAAP EPS of $2.05 Includes Net Impact of
Bristol Myers Squibb reported its first quarter financial results for 2023, showcasing revenues totaling $11.3 billion, which represents a 3% decrease year-over-year. However, the company showed significant improvement in GAAP EPS, which rose by 81% to $1.07, and confirmed its non-GAAP guidance for the year. Strong revenue growth was reported from in-line products and the new product portfolio, particularly in the U.S. Despite mixed international performance and challenges from generic erosion, the company remains optimistic about its strategic initiatives and pipeline advancements.
Read more →BMYBristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022 Reports Fourth Quarter Revenues of $11.4 Billion Full-Year Revenues of $46.2 Billion Fourth Quarter Revenues from In-Line Products and
Bristol Myers Squibb reported its financial results for Q4 and full year 2022, revealing fourth quarter revenues of $11.4 billion and full-year revenues of $46.2 billion. While there was a 5% decline in total revenues for Q4 compared to 2021, in-line products and the new product portfolio showed a significant increase of 7%. The company’s GAAP EPS for Q4 was reported at $0.95. CEO Giovanni Caforio emphasized the company's strong financial performance and optimistic outlook, despite challenges such as a decline in international revenues and increased manufacturing costs.
Read more →BMYBrasil deve ter mais de 180 mil novos casos de Câncer de Pele até o fim deste ano Bristol Myers Squibb. O câncer de pele corresponde a cerca de um terço de todos os casos de Câncer diagnosticados no Brasil. Dados do INCA, o...
Doença depende do diagnóstico precoce para sucesso no tratamento SÃO PAULO , 21 de dezembro de 2022 /PRNewswire/ -- Bristol Myers Squibb. O câncer de pele corresponde a cerca de um terço de todos os casos de Câncer diagnosticados no Brasil. Dados do INCA, o Instituto Nacional do
Read more →BMYBristol Myers Squibb Reports Third Quarter Financial Results for 2022 Reports Third Quarter Revenues of $11.2 Billion Delivers Strong Revenue Growth of 8% from In-Line Products and New Product Portfolio or 13% When Adjus
Bristol Myers Squibb Reports Third Quarter Financial Results for 2022 Reports Third Quarter Revenues of $11.2 Billion Delivers Strong Revenue Growth of 8% from In-Line Products and New Product Portfolio or 13% When Adjusted for Foreign Exchange Posts Third Quarter Earnings Per
Read more →BMYBristol Myers Squibb Reports Second Quarter Financial Results for 2022 Reports Second Quarter Revenues of $11.9 Billion, an Increase of 2% YoY or 5% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Sh
Bristol Myers Squibb Reports Second Quarter Financial Results for 2022 Reports Second Quarter Revenues of $11.9 Billion, an Increase of 2% YoY or 5% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Share of $0.66 and Non-GAAP EPS of $1.93 Includes Net Impact
Read more →BMYBristol Myers Squibb Elects Deepak L. Bhatt, M.D., M.P.H. to Board of Directors
Bristol Myers Squibb Elects Deepak L. Bhatt, M.D., M.P.H. to Board of Directors NEW YORK, NY- June 15, 2022 - Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected Deepak L. Bhatt, M.D., MPH., to the Board, effective June 14, 2022. Dr. Bhatt
Read more →BMYBristol Myers Squibb Reports First Quarter Financial Results for 2022 Reports First Quarter Revenues of $11.6 Billion, an Increase of 5% YoY or 7% When Adjusted for Foreign Exchange Posts First Quarter Earnings Per Share
Bristol Myers Squibb Reports First Quarter Financial Results for 2022 Reports First Quarter Revenues of $11.6 Billion, an Increase of 5% YoY or 7% When Adjusted for Foreign Exchange Posts First Quarter Earnings Per Share of $0.59 and Non-GAAP EPS of $1.96 Includes Net Impact of
Read more →BMYBRISTOL-MYERS SQUIBB COMPANY EARNINGS FROM OPERATIONS (Unaudited, dollars and shares in millions except per share data) 2020 2021 Year 1st Qtr 2nd Qtr 3rd Qtr 4th Qtr Year Net product sales $ 41,321 $ 10,798 $ 11,405 $ 1
BRISTOL-MYERS SQUIBB COMPANY EARNINGS FROM OPERATIONS (Unaudited, dollars and shares in millions except per share data) 2020 2021 Year 1st Qtr 2nd Qtr 3rd Qtr 4th Qtr Year Net product sales $ 41,321 $ 10,798 $ 11,405 $ 11,243 $ 11,609 $ 45,055 All
Read more →BMYBristol Myers Squibb Announces Early Participation Results, Upsizing and Early Settlement of Tender Offers (NEW YORK
Bristol Myers Squibb Announces Early Participation Results, Upsizing and Early Settlement of Tender Offers (NEW YORK, March 1, 2022) - Bristol-Myers Squibb Company (NYSE: BMY) ("Bristol Myers Squibb"), with its wholly-owned subsidiary Celgene Corporation ("Celgene") (collectiv
Read more →BMYBristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion (NEW YORK
Bristol Myers Squibb Announces Tender Offers for an Aggregate Purchase Price of Up to $4.0 (NEW YORK, February 15, 2022) - Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol Myers Squibb"), with its wholly-owned subsidiary Celgene Corporation ("Celgene") (collectively, the "Off
Read more →BMYBristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes
EX-99.1 3 ny20002727x5_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Bristol Myers Squibb Prices $6 Billion of Senior Unsecured Notes NEW YORK, February 15, 2022-- Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has priced a public offering (the "Offering") of senior unsec
Read more →BMYBristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021 Reports Fourth Quarter Revenues of $12.0 Billion Full-Year Revenues of $46.4 Billion Posts Fourth Quarter Earnings Per Share of $1.07 a
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021 Reports Fourth Quarter Revenues of $12.0 Billion Full-Year Revenues of $46.4 Billion Posts Fourth Quarter Earnings Per Share of $1.07 and Non-GAAP EPS of $1.83 Posts Full- Year Earnings Per Sha
Read more →BMYCampanha Sobre Viver conta histórias de superação de pacientes oncológicos Viver com câncer é um desafio, mas também pode ser uma trajetória de conquistas e superação. Isso é o que conta a campanha Sobre Viver - Como é viver ...
SÃO PAULO, 10 de janeiro de 2022 /PRNewswire/ -- Viver com câncer é um desafio, mas também pode ser uma trajetória de conquistas e superação. Isso é o que conta a campanha Sobre Viver - Como é viver com câncer hoje? que, por meio de histórias inspiradoras dos pacientes com câncer
Read more →BMYInvestor Event
Investor Event November 16, 2021 Forward Looking Statement and Non-GAAP Financial Information 2 This presentation contains statements about the Company's future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the P
Read more →BMYBristol Myers Squibb Reports Third Quarter Financial Results for 2021 Reports Third Quarter Revenues of $11.6 Billion, an Increase of 10% YoY Posts Third Quarter Earnings Per Share of $0.69 and Non-GAAP EPS of $2.00 Adva
Bristol Myers Squibb Reports Third Quarter Financial Results for 2021 Reports Third Quarter Revenues of $11.6 Billion, an Increase of 10% YoY Posts Third Quarter Earnings Per Share of $0.69 and Non-GAAP EPS of $2.00 Advances Product Pipeline with Significant Regulatory and Cli
Read more →BMYANVISA aprova dupla imunoterapia para tratamento de câncer de pulmão em primeira linha A ANVISA (Agência Nacional de Vigilância Sanitária) acaba de aprovar nivolumabe em combinação com ipilimumabe e dois ciclos de quimioterapia à base...
SÃO PAULO, 13 de setembro de 2021 /PRNewswire/ -- A ANVISA (Agência Nacional de Vigilância Sanitária) acaba de aprovar nivolumabe em combinação com ipilimumabe e dois ciclos de quimioterapia à base de platina para o tratamento de primeira linha de câncer de pulmão de células não
Read more →BMYBristol Myers Squibb Reports Second Quarter Financial Results for 2021 Reports Second Quarter Revenues of $11.7 Billion, an Increase of 16% YoY, or 13% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per
Bristol Myers Squibb Reports Second Quarter Financial Results for 2021 Reports Second Quarter Revenues of $11.7 Billion, an Increase of 16% YoY, or 13% When Adjusted for Foreign Exchange Posts Second Quarter Earnings Per Share of $0.47 and Non-GAAP EPS of $1.93 Delivers Strong
Read more →BMYApós dez anos sem inovação, Anvisa aprova nova alternativa para o tratamento do câncer gástrico Após dez anos sem inovação no tratamento do câncer gástrico, a Anvisa acaba de aprovar nivolumabe (injeção para uso intravenoso) em combinação com...
SÃO PAULO, 1 de julho de 2021 /PRNewswire/ -- Após dez anos sem inovação no tratamento do câncer gástrico, a Anvisa acaba de aprovar nivolumabe (injeção para uso intravenoso) em combinação com quimioterapia contendo fluoropirimidina e platina para o tratamento de pacientes com ad
Read more →BMYTabagismo é um dos maiores responsáveis pela incidência do câncer renal Silenciosamente, é assim que o câncer de rim se apresenta. Considerado o 12º tipo de câncer mais comum no mundo2, cuja prevalência é maior entre os...
SÃO PAULO, 17 de junho de 2021 /PRNewswire/ -- Silenciosamente, é assim que o câncer de rim se apresenta. Considerado o 12º tipo de câncer mais comum no mundo 2 , cuja prevalência é maior entre os homens 2 , com idade média de 64 anos 2 , a doença recebe destaque no Junho Verde ,
Read more →BMY#MaisPróximosMaisFortes intensifica movimento de conscientização sobre mieloma múltiplo Para um indivíduo acima dos 40 anos, uma dor na lombar pode representar muitos quadros. Pode ser apenas o reflexo de uma noite mal dormida, talvez...
Campanha que reúne Amgen e Bristol Myers Squibb reforça a importância do diagnóstico precoce no tratamento do segundo tipo de câncer de sangue mais frequente no mundo [i] SÃO PAULO, 26 de maio de 2021 /PRNewswire/ -- Para um indivíduo acima dos 40 anos, uma dor na lombar pode re
Read more →BMYBristol Myers Squibb Elects Manuel Hidalgo Medina, M.D., Ph.D. to Board of Directors
Bristol Myers Squibb Elects Manuel Hidalgo Medina, M.D., Ph.D. to Board of Directors NEW YORK, NY- May 20, 2021 - Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected Manuel Hidalgo Medina, M.D., Ph.D., to the Board, effective June 1, 2021.
Read more →BMYBristol Myers Squibb Reports First Quarter Financial Results for 2021 Reports First Quarter Revenues of $11.1 Billion, an Increase of 3% YoY Revenue Increase of 8% Excluding COVID-19 Related Buying Patterns from Prior Ye
Bristol Myers Squibb Reports First Quarter Financial Results for 2021 Reports First Quarter Revenues of $11.1 Billion, an Increase of 3% YoY Revenue Increase of 8% Excluding COVID-19 Related Buying Patterns from Prior Year Period Posts First Quarter Earnings Per Share of $0.89
Read more →BMYBristol Myers Squibb Announces Early Participation Results and Early Settlement of Tender Offers for Up to an Aggregate Purchase Price of Up to $4.0 Billion (NEW YORK
Bristol Myers Squibb Announces Early Participation Results and Early Settlement of Tender Offers for Up to an Aggregate Purchase Price of Up to $4.0 Billion (NEW YORK, February 18, 2021) - Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol Myers Squibb"), with its wholly-owned s
Read more →BMYBristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020 Reports Fourth Quarter Revenues of $11.1 Billion Full-Year Revenues of $42.5 Billion Posts Fourth Quarter Loss Per Share of $4.45 and N
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2020 Reports Fourth Quarter Revenues of $11.1 Billion Full-Year Revenues of $42.5 Billion Posts Fourth Quarter Loss Per Share of $4.45 and Non-GAAP EPS of $1.46 Full-Year Loss Per Share of $3.99 and
Read more →BMYINVESTOR PRESENTATION OF BRISTOL-MYERS SQUIBB COMPANY J.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference January 11, 2021 Forward Looking Statement and Non-GAAP Financial Information * This presentation contains statements about the Company's future plans and prospects that constitute forward-looking statements for purposes of the safe harbor prov
Read more →BMYBristol Myers Squibb Provides Update on Status of Contingent Value Rights (PRINCETON, N.J.
Bristol Myers Squibb Provides Update on Status of Contingent Value Rights (PRINCETON, N.J., January 1, 2021) - Bristol Myers Squibb (NYSE: BMY) today announced that the Biologics License Application (BLA) for lisocabtagene maraleucel (liso-cel) for the treatment of adults with
Read more →BMYAnvisa aprova imunoterápico para tratamento de câncer de esôfago A Agência Nacional de Vigilância Sanitária (Anvisa) aprovou em tempo recorde a indicação de Opdivo® (nivolumabe) para tratamento de segunda linha do...
SÃO PAULO, 17 de dezembro de 2020 /PRNewswire/ -- A Agência Nacional de Vigilância Sanitária (Anvisa) aprovou em tempo recorde a indicação de Opdivo® (nivolumabe) para tratamento de segunda linha do câncer de esôfago. O resultado foi obtido após dois meses de submissão do pedido,
Read more →BMYBristol Myers Squibb Prices $7 Billion of Senior Unsecured Notes
Bristol Myers Squibb Prices $7 Billion of Senior Unsecured Notes NEW YORK, November 9, 2020--Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has priced a public offering (the "Offering") of senior unsecured notes in a combined aggregate principal amount of $7 bi
Read more →BMYBristol Myers Squibb Reports Third Quarter 2020 Financial Results Reports Third Quarter Revenues of $10.5 Billion Posts GAAP EPS of $0.82 and Non-GAAP EPS of $1.63 Extends and Strengthens Leading Cardiovascular Franchise
Bristol Myers Squibb Reports Third Quarter 2020 Financial Results Reports Third Quarter Revenues of $10.5 Billion Posts GAAP EPS of $0.82 and Non-GAAP EPS of $1.63 Extends and Strengthens Leading Cardiovascular Franchise with Planned MyoKardia Acquisition Delivers Significant
Read more →BMYBristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyop
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Mavacamten Will Be a Medium- and Long-Term Growth Driver Presenting
Read more →BMYMês de Conscientização dos Cânceres de Sangue Pacientes que enfrentam cânceres hematológicos são os mais suscetíveis a complicações decorrentes da Covid-191. Essa afirmação baseia-se no...
Pacientes com mieloma múltiplo estão entre os mais vulneráveis às complicações da Covid-19 Enfrentamento do câncer durante a pandemia exige atenção especial à saúde mental SÃO PAULO, 22 de setembro de 2020 /PRNewswire/ -- Pacientes que enfrentam cânceres hematológicos são os ma
Read more →BMYBristol Myers Squibb Reports Second Quarter 2020 Financial Results Reports Second Quarter Revenues of $10.1 Billion Posts GAAP Loss Per Share of $0.04 and Non-GAAP EPS of $1.63 Advances Pipeline with Positive Topline Res
Bristol Myers Squibb Reports Second Quarter 2020 Financial Results Reports Second Quarter Revenues of $10.1 Billion Posts GAAP Loss Per Share of $0.04 and Non-GAAP EPS of $1.63 Advances Pipeline with Positive Topline Results for Zeposia in Ulcerative Colitis Approvals for Opdi
Read more →BMYBristol Myers Squibb Board Elects Two New Independent Directors
Bristol Myers Squibb Board Elects Two New Independent Directors NEW YORK, NY- July 30, 2020 - Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected two new independent directors, Ms. Paula A. Price and Mr. Derica W. Rice, who will join the Boar
Read more →BMYBristol Myers Squibb Announces Expiration and Final Results of Registered Exchange Offers PRINCETON, N.J.
Bristol Myers Squibb Announces Expiration and Final Results of Registered Exchange Offers PRINCETON, N.J. July 16, 2020 - Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol Myers Squibb") announced today the expiration and final results of its offers to exchange (the "Registered
Read more →BMYBristol Myers Squibb Announces Commencement of Registered Exchange Offers PRINCETON, N.J.
Bristol Myers Squibb Announces Commencement of Registered Exchange Offers PRINCETON, N.J. June 16, 2020 - Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol Myers Squibb") announced today the commencement of its offers to exchange (the "Registered Exchange Offers") any and all o
Read more →BMYUNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information is presented to illustrate the estimated effects of: the merger of Bristol-Myers Squ
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial information is presented to illustrate the estimated effects of: The unaudited pro forma condensed combined statement of earnings for the year ended Decem
Read more →BMYBristol Myers Squibb Reports Strong First Quarter 2020 Financial Results Reports First Quarter Revenues of $10.8 Billion, an Increase of 82%; On a Pro Forma Basis, Revenue Increase of 13% or 8% Excluding Impact of COVID-
Bristol Myers Squibb Reports Strong First Quarter 2020 Financial Results (NEW YORK, May 7, 2020) - Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2020, which highlight strong sales, robust operating performance and significant advancement of the c
Read more →BMYBristol Myers Squibb Announces Virtual 2020 Annual Meeting of Shareholders
Bristol Myers Squibb Announces Virtual 2020 Annual Meeting of Shareholders NEW YORK - April 14, 2020 - Bristol Myers Squibb (NYSE: BMY) today announced that the Company will hold its 2020 Annual Meeting of Shareholders in a virtual-only format due to public health concerns rela
Read more →BMYAs of 3/25/2020 Investor Fact Sheet related to COVID-19 Contents Manufacturing and Supply 2 Workforce 2 Commercial 3 Clinical Trial Conduct 3 Balance Sheet and Capital Allocation 3 Regulatory 4 As of 3/25/2020 Manufactur
Investor Fact Sheet related to COVID-19 Manufacturing and Supply 2 Workforce 2 Commercial 3 Clinical Trial Conduct 3 Balance Sheet and Capital Allocation 3 Regulatory 4 Manufacturing and Supply Bristol Myers Squibb is diligently monitoring manufacturing and supply facilities a
Read more →BMYBristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results for 2019 Reports Fourth Quarter Revenues of $7.9 Billion; $26.1 Billion for Full Year Posts Fourth Quarter GAAP Loss Per Share of $0.55 and Non-
Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results for 2019 (NEW YORK, February 6, 2020) - Bristol-Myers Squibb Company (NYSE:BMY) today reports results for the fourth quarter and full year of 2019, which highlight continued strong sales and robust opera
Read more →BMYBristol-Myers Squibb Company Announces Final Results of Exchange Offers for Celgene Corporation Notes
Bristol-Myers Squibb Company Announces Final Results of Exchange Offers for Celgene Corporation Notes NEW YORK, November 21, 2019 - Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the final results of the offers to exchange (the "Exchange Offers
Read more →BMYBristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company
Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company NEW YORK- November 20, 2019 - Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of
Read more →BMYBristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition Company Has Now Satisfied All Regulatory Approvals for Celgene Acquisition Transaction Expected to Close on
Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition Company Has Now Satisfied All Regulatory Approvals for Celgene Acquisition Transaction Expected to Close on November 20, 2019 FTC Approves Agreement between Celgene and Amgen to
Read more →BMYBristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes
Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes NEW YORK, November 15, 2019 - Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today the extension of the expiration date of the o
Read more →BMYBristol-Myers Squibb Reports Third Quarter Financial Results Increases Third Quarter Revenues 6% to $6.0 Billion Posts Third Quarter GAAP EPS of $0.83 and Non-GAAP EPS of $1.17 Announces CheckMate -9LA Meets Primary Endp
Bristol-Myers Squibb Reports Third Quarter Financial Results (NEW YORK, October 31, 2019) - Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the third quarter of 2019, which were highlighted by strong sales and a robust operating performance, along with the con
Read more →BMYBristol-Myers Squibb Board Announces Election of Three New Directors Mr. Michael Bonney, Dr. Julia A. Haller and Ms. Phyllis Yale to Join BMS Board as Independent Directors (NEW YORK
Bristol-Myers Squibb Board Announces Election of Three New Directors Mr. Michael Bonney, Dr. Julia A. Haller and Ms. Phyllis Yale to Join BMS Board as Independent Directors (NEW YORK, September 11, 2019) - Bristol-Myers Squibb Company (NYSE:BMY) today announced that its Board
Read more →BMYBristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA for $13.4 Billion Agreement Contingent on FTC Consent Decree and Closing of Pending Bristol-Myers Squibb-Celgene M
Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA for $13.4 Billion Agreement Contingent on FTC Consent Decree and Closing of Pending Bristol-Myers Squibb-Celgene Merger Pending Bristol-Myers Squibb-Celgene Merger Expected to Close by End of 20
Read more →BMYBristol-Myers Squibb Reports Second Quarter Financial Results Increases Second Quarter Revenues 10% to $6.3 Billion Posts Second Quarter GAAP EPS of $0.87 and Non-GAAP EPS of $1.18 Announces Topline Results for CheckMate
Bristol-Myers Squibb Reports Second Quarter Financial Results (NEW YORK, July 25, 2019) - Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the second quarter of 2019, which were highlighted by strong sales for Eliquis (apixaban) and Opdivo (nivolumab) and a rob
Read more →BMYBristol-Myers Squibb Completes Divestment of UPSA (NEW YORK
Bristol-Myers Squibb Completes Divestment of UPSA (NEW YORK, July 1, 2019) - Bristol-Myers Squibb Company (NYSE:BMY) announced today that effective July 1, 2019 it has completed its previously announced divestment of its consumer health business, UPSA, to Taisho Pharmaceutical
Read more →BMYBristol-Myers Squibb Provides Update on Pending Merger with Celgene
Bristol-Myers Squibb Provides Update on Pending Merger with Celgene NEW YORK, June 24, 2019 - Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company's pending merger with Celgene Corporation (NASDAQ: CELG). The Com
Read more →BMYBristol-Myers Squibb Announces Post-Closing Leadership Team Experienced leadership team and evolved structure position company to drive in-line business, launch new products and create long-term val
Bristol-Myers Squibb Announces Post-Closing Leadership Team (NEW YORK, June 5, 2019) - Bristol-Myers Squibb Company (NYSE:BMY) today announced the future leadership team of the combined company effective upon completion of the company's pending merger with Celgene Corporation (
Read more →BMYBristol-Myers Squibb Company Prices $19 Billion of Senior Unsecured Notes
EX-99.1 3 nc10001539x3_ex99-1.htm PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY Exhibit 99.1 Bristol-Myers Squibb Company Prices $19 Billion of Senior Unsecured Notes NEW YORK, May 7, 2019-- Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") today announced that it
Read more →BMYBristol-Myers Squibb Company Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Celgene Corporation Notes
Bristol-Myers Squibb Company Announces Results of Early Participation in Exchange Offers and Consent Solicitations for Celgene Corporation Notes NEW YORK, May 1, 2019 - Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb") announced today that the requisite number of
Read more →BMYSOURCES AND USES OF FUNDS AND PRO FORMA CAPITALIZATION The table below sets forth the estimated sources and uses of funds in connection with certain transactions in connection with the Merger, assuming they occurred on
SOURCES AND USES OF FUNDS AND PRO FORMA CAPITALIZATION The table below sets forth the estimated sources and uses of funds in connection with certain transactions in connection with the Merger, assuming they occurred on March 31, 2019 and based on estimated amounts outstanding o
Read more →BMYCELGENE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (Dollars in millions, except per share amounts) Three-Month Periods Ended
CELGENE CORPORATION AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME (Dollars in millions, except per share amounts) Three-Month Periods Ended March 31, 2019 2018 Revenue: Net product sales $ 4,024 $ 3,531 Other revenue 1 7 Total revenue 4,025 3,538 Expe
Read more →BMYBristol-Myers Squibb Reports First Quarter Financial Results Increases First Quarter Revenues 14% to $5.9 Billion Posts First Quarter GAAP EPS of $1.04 and Non-GAAP EPS of $1.10 Announces Shareholder Approval of Celgene
Bristol-Myers Squibb Reports First Quarter Financial Results (NEW YORK, April 25, 2019) - Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (apixaban) and a robu
Read more →BMYBristol-Myers Squibb Company Announces Commencement of Exchange Offers and Consent Solicitations for Celgene Notes
Bristol-Myers Squibb Company Announces Commencement of Exchange Offers and Consent Solicitations for Celgene Notes NEW YORK, April 17, 2019 - Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb) announced today the commencement, in connection with its previously anno
Read more →BMYBristol-Myers Squibb Shareholders Approve Celgene Acquisition Transaction on Track to Close in Third Quarter of 2019
Bristol-Myers Squibb Shareholders Approve Celgene Acquisition Transaction on Track to Close in Third Quarter of 2019 NEW YORK, April 12, 2019 - Bristol-Myers Squibb Company (NYSE: BMY) today announced that its shareholders voted to approve the issuance of shares of Bristol-Mye
Read more →Competitive Position
How BMY ranks across every disease it competes inCompetitive Position is a premium feature
See how BMY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial